CorMedix CRMD · Forecast & Analysis
CRMD rates bullish after agreeing to buy Heron Therapeutics' hospital products, a deal management calls immediately accretive with sizable cost synergies. Closing is only expected in Q1 2027 and the share issuance dilutes existing holders.
News situation · 1 items / 30 D
1 of 1 straight from the issuer or regulator
Outlook for CorMedix
Direction, typical moves and upcoming dates from our own price, news and calendar data, recalculated on every visit. An assessment, not investment advice.
What drives it
- The November 9 agreement adds four commercial-stage hospital products for about $222.6 million upfront.
- Guided operating cost synergies of $45-$60 million, with the deal immediately accretive to earnings and free cash flow.
- A $75 million Pharmakon loan funds the cash portion without adding further dilution.
What argues against it
- Closing is only expected in Q1 2027, pending Heron stockholder approval and antitrust clearance.
- 14,583,333 new shares plus Rubric's exchange of roughly $37.8 million in convertible notes dilute holders.
- High-impact US inflation data is due shortly, event risk that can swing the wider market.
What would change the picture
- Progress on Heron stockholder approval and antitrust clearance would move the deal toward closing.
- An unexpectedly hot or cool US inflation print could reset the macro backdrop for the shares.
Coming up
- US: Jobless claims
- US: EIA Crude Oil Stocks Change
- US: Producer prices · expected 0.4%, previous 0.7%
Economic data for CRMD
Full calendarRecently released
- TodayUSDCore CPI●●●Forecast 339.796Previous 338.896
- TodayUSDCore CPI y/y●●●Forecast 2.8%Previous 2.6%
- TodayUSDCPI y/y●●●Forecast 4.2%Previous 3.7%
- TodayUSDCore CPI m/m●●●Forecast 0.2%Previous 0.3%
- TodayUSDCPI●●●Forecast 338.683Previous 336.298
- TodayUSDCPI m/m●●●Forecast 0.5%Previous 0.6%
- TodayUSDCore CPI n.s.a. m/m●●●Previous 0.4%
Coming up
- November 12, 2026USDInitial Jobless Claims●●●in 1 day
- November 12, 2026USDEIA Crude Oil Stocks Change●●●in 2 days
- November 13, 2026USDCore PPI m/m●●●Forecast 0.4%Previous 0.7%in 2 days
- November 13, 2026USDPPI m/m●●●Forecast 0.4%Previous 1.3%in 2 days
- November 17, 2026USDRetail Sales m/m●●●Forecast 0.3%Previous 0.8%in 6 days
- November 17, 2026USDCore Retail Sales m/m●●●Forecast 0.7%Previous 0.9%in 6 days
All times UTC. Assessed against the consensus forecast, otherwise against the previous value.
Both worlds over time
Technical and news signals of the last 30 days on one timeline.
What is being reported about CRMD
Frequently asked questions about CorMedix
What does the Heron Therapeutics deal mean for CorMedix?
CorMedix agreed on November 9 to buy substantially all assets of Heron Therapeutics: four commercial-stage hospital products for $145 million in cash plus 14,583,333 shares, roughly $222.6 million upfront. Management guides to $45-$60 million of operating cost synergies and calls the deal immediately accretive to earnings and free cash flow.
How is the acquisition financed, and what is the dilution?
The cash portion is funded by a $75 million Pharmakon loan that management describes as non-dilutive. Still, 14,583,333 new shares go to Heron holders, and Rubric exchanges roughly $37.8 million of convertible notes into CorMedix shares, so existing holders face meaningful dilution on top of the cash consideration.
What could change the picture for CRMD from here?
The main swing factors are the deal's conditions: Heron stockholder approval and antitrust clearance, with closing only expected in Q1 2027. Whether the guided synergies materialise matters too. Beyond the company, high-impact US inflation figures due shortly set the macro backdrop for shares like CRMD.
📝 Overview Generated automatically
CRMD has been the subject of 1 signals across 1 articles in the last 365 days. Sentiment skews Bullish (100%).
Breakdown: 1 bullish, 0 bearish, 0 neutral.
Most-cited catalysts: Definitive agreement announced November 9, 2026 to acquire substantially all assets of Heron Therapeutics (1×), Estimated $45-$60 million in near-term operating cost synergies and immediate earnings/free cash flow accretion (1×). Most-cited risk factors: Closing only expected in Q1 2027, subject to Heron stockholder approval, HSR antitrust clearance and other conditions (1×), Issuance of 14,583,333 fixed shares plus Rubric's exchange of roughly $37.8 million of convertible notes into CorMedix shares dilutes existing holders (1×).
Related assets
Same category or comparable signal picture — each card opens the full cockpit.